In a nutshell This study evaluated the benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery (CS) for the treatment of colorectal cancer (CRC) that has spread to the peritoneum (the lining of the abdomen that covers all abdominal organs). The study found that HIPEC added to CS did not improve the outcomes of...
Read MoreCurrent stage-Stage IV Posts on Medivizor
Do single or combined immune checkpoint inhibitors improve outcomes in patients with advanced non-small cell lung cancer?
In a nutshell This article looked at the effectiveness and safety of first-line immune checkpoint inhibitors (ICIs) alone or as a combination compared to platinum-based chemotherapy (PBC) for advanced non-small cell lung cancer (NSCLC). The authors found that ICI therapy may improve the survival of these patients while having reduced side...
Read MoreSearching for patients to trial an experimental medication for advanced solid tumors.
In a nutshell This trial is aiming to examine the safety and effectiveness of experimental treatment DF6002 alone or in combination with nivolumab (Opdivo) in the treatment of advanced solid tumors, including lung cancer. The main outcomes to be measured are drug toxicity and the response rate of patients to the drug. This trial is being carried out in...
Read MoreDoes continuous nivolumab improve outcomes in advanced non-small cell lung cancer?
In a nutshell This study compared 1-year fixed-duration versus continuous nivolumab (Opdivo) for the treatment of previously treated advanced non-small-cell lung cancer (NSCLC). The authors found that continuing nivolumab beyond a fixed duration of 1-year may improve patient outcomes. Some background NSCLC is the most common form of lung cancer....
Read MoreLiver partition and portal vein ligation improves long-term outcomes of patients with colorectal cancer and liver metastases
In a nutshell This study investigated the long-term outcomes of patients with colorectal cancer (CRC) and liver metastases (LM; cancer spread to the liver) undergoing the ALPPS (associating liver partition and portal vein ligation) procedure. Researchers suggested that patients with LM that were unfit for surgical removal achieved positive long-term...
Read MoreSearching for patients with advanced breast cancer to trial an experimental combination treatment.
In a nutshell This trial is looking to examine the safety and effectiveness of a new drug called CYH33 in combination with olaparib (Lynparza) for the treatment of advanced solid tumors including breast cancer. The main outcomes that are to be measured are side effects and the response rate to the treatment. This trial is being carried out in...
Read MoreLong-term outcomes for nivolumab in patients with BRAF-negative advanced melanoma
In a nutshell This study investigated the long-term effectiveness and safety of immunotherapy drug nivolumab (Opdivo) compared to chemotherapy drug dacarbazine (DTIC-Dome) for patients with BRAF-negative advanced melanoma. The study showed that nivolumab significantly increased survival in these...
Read MoreTreating postmenopausal women with HER2- and hormone-receptor positive metastatic breast cancer with lapatinib, trastuzumab and aromatase inhibitor
In a nutshell The study evaluated outcomes of lapatinib (Tykerb), trastuzumab (Herceptin), and aromatase inhibitor (AI) in postmenopausal women with human epidermal growth factor receptor 2-positive (HER2+) and hormone receptor-positive (HR+) metastatic breast cancer (MBC). The authors found that the combination was safe and effective in such...
Read MoreComparing nivolumab and ipilimumab treatment after surgery for advanced melanoma
In a nutshell This study compared nivolumab (Opdivo) and ipilimumab (Yervoy) for treating advanced melanoma that has been surgically removed. They found that patients treated with nivolumab survived cancer-free for longer than patients treated with ipilimumab. Some background Melanoma which has spread to the lymph nodes or other organs is...
Read MoreLooking for patients with advanced breast cancer to trial an experimental drug treatment.
In a nutshell This trial is aiming to examine the effectiveness of an experimental drug, AMXI-5001, in patients with advanced breast cancer. The main outcomes that are to be measured in this trial are side effects and the response to treatment. This trial is going to be carried out in California, Tennessee, and Florida, the United States. The...
Read MoreSearching for patients with advanced triple-negative breast cancer to trial a treatment combination
In a nutshell This trial is aiming to examine the effectiveness of ipatasertib in combination with atezolizumab (Tecentriq) and paclitaxel (Taxol) for the treatment of advanced triple-negative breast cancer (TNBC) that cannot be surgically removed. The main outcomes to be measured in this trial is survival without progression of the disease and...
Read MoreLooking for patients with advanced melanomas to trial an experimental treatment in combination with pembrolizumab.
In a nutshell This trial is aiming to examine the effectiveness of APG-115 with pembrolizumab (Keytruda) in the treatment of metastatic melanoma. The main outcomes to be measured will be the maximum dose tolerated and the overall response to the drug. This trial is recruiting in multiple locations in the United States. The details...
Read More